IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 388 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 1.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $663 | +127.1% | 14,612 | +105.5% | 1.89% | +140.1% |
| Q2 2023 | $292 | +15.0% | 7,112 | 0.0% | 0.79% | +6.9% |
| Q1 2023 | $254 | -5.6% | 7,112 | 0.0% | 0.74% | -13.5% |
| Q4 2022 | $269 | -99.9% | 7,112 | 0.0% | 0.85% | -9.3% |
| Q3 2022 | $315,000 | +19.8% | 7,112 | 0.0% | 0.94% | +9.9% |
| Q2 2022 | $263,000 | -17.0% | 7,112 | -16.8% | 0.86% | +33.6% |
| Q1 2022 | $317,000 | +17.4% | 8,547 | -3.6% | 0.64% | +24.8% |
| Q4 2021 | $270,000 | -51.7% | 8,862 | -46.8% | 0.51% | -35.6% |
| Q3 2021 | $559,000 | -15.9% | 16,661 | 0.0% | 0.80% | -11.2% |
| Q2 2021 | $665,000 | -28.3% | 16,661 | -19.2% | 0.90% | -23.6% |
| Q1 2021 | $927,000 | -2.4% | 20,611 | +22.6% | 1.18% | -44.2% |
| Q4 2020 | $950,000 | +8.1% | 16,806 | -9.3% | 2.11% | -23.4% |
| Q3 2020 | $879,000 | -23.6% | 18,521 | -5.2% | 2.75% | -22.8% |
| Q2 2020 | $1,151,000 | +21.5% | 19,529 | -2.5% | 3.57% | -13.9% |
| Q1 2020 | $947,000 | -47.9% | 20,040 | -33.4% | 4.14% | -28.1% |
| Q4 2019 | $1,819,000 | -1.0% | 30,107 | -1.9% | 5.76% | -2.9% |
| Q3 2019 | $1,838,000 | -12.5% | 30,677 | -6.1% | 5.94% | -7.8% |
| Q2 2019 | $2,100,000 | -24.8% | 32,670 | -5.0% | 6.43% | -23.6% |
| Q1 2019 | $2,792,000 | +41.7% | 34,391 | -5.7% | 8.42% | +34.4% |
| Q4 2018 | $1,971,000 | +4.0% | 36,460 | -0.7% | 6.26% | +42.3% |
| Q3 2018 | $1,895,000 | +23.8% | 36,735 | 0.0% | 4.40% | +19.9% |
| Q2 2018 | $1,531,000 | -30.9% | 36,735 | -26.9% | 3.67% | -30.7% |
| Q1 2018 | $2,215,000 | -16.1% | 50,250 | -4.3% | 5.30% | -12.2% |
| Q4 2017 | $2,640,000 | -16.2% | 52,481 | -15.5% | 6.03% | -14.1% |
| Q3 2017 | $3,149,000 | -24.4% | 62,101 | -24.2% | 7.02% | -26.5% |
| Q2 2017 | $4,168,000 | +24.3% | 81,937 | -1.8% | 9.55% | +29.2% |
| Q1 2017 | $3,353,000 | -17.5% | 83,399 | -1.8% | 7.39% | -22.2% |
| Q4 2016 | $4,063,000 | +71.2% | 84,953 | +31.2% | 9.51% | +67.1% |
| Q3 2016 | $2,373,000 | – | 64,770 | – | 5.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |